Karyopharm Therapeutics, Inc. (KPTI)
0.0549
-0.01
(-8.65%)
USD |
NASDAQ |
Nov 06, 16:00
0.0462
-0.01
(-15.85%)
After-Hours: 20:00
Karyopharm Therapeutics Research and Development Expense (Annual) : 125.32M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 125.32M |
| December 31, 2024 | 142.89M |
| December 31, 2023 | 138.22M |
| December 31, 2022 | 148.04M |
| December 31, 2021 | 152.70M |
| December 31, 2020 | 149.84M |
| December 31, 2019 | 121.37M |
| December 31, 2018 | 161.37M |
| Date | Value |
|---|---|
| December 31, 2017 | 107.27M |
| December 31, 2016 | 86.94M |
| December 31, 2015 | 97.74M |
| December 31, 2014 | 60.13M |
| December 31, 2013 | 28.45M |
| December 31, 2012 | 14.10M |
| December 31, 2011 | 8.623M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Heron Therapeutics, Inc. | 12.43M |
| Tonix Pharmaceuticals Holding Corp. | 44.49M |
| Minerva Neurosciences, Inc. | 5.760M |
| Corbus Pharmaceuticals Holdings, Inc. | 70.10M |
| Ocugen, Inc. | 37.36M |